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The purpose of this study was to assess (1) the incidence of safety margin testing <10 J
(SMT) and (2) the efficacy/safety of routinely adding a subcutaneous array (SQA) (Medtronic
6996SQ) for these patients.
Patients with SMT smaller than a 10-J safety margin from maximum output were
considered to have very high readings and underwent SQA insertion. These patients were
compared with the rest of the patients who had acceptable SMT (10 J).
A total of 616 patients underwent ICD implantation during the analysis period. Of those,
16 (2.6%) had SMT <10 J. By univariate analysis, younger age, and non-ischemic cardio-
myopathy, were all significant predictors of SMT <10 J (p < 0.05). In all 16 cases, other
methods to improve SMT prior to array insertion were attempted but failed for all patients:
reversing shock polarity (n ¼ 15), removing the superior vena cava coil (n ¼ 14), reprog-
ramming shock waveform (n ¼ 9), and repositioning right ventricular lead (n ¼ 9). Addition
of the SQA successfully increased SMT to within safety margin for all patients (32 ± 2
versus 21 ± 3 J; p < 0.001). Follow-up (mean 48.1 ± 21 months) was available for all patients
with SQA, only 2 cases with inappropriate shocks due to atrial fibrillation had to be noted.
None of the patients experienced complications due to SQA implantation.
SMT <10 J occur in about 2.6% of patients undergoing ICD implantation. SQA insertion
corrects this problem without procedural/mid-term complications.
Copyright © 2016, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.
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The implantable cardioverter defibrillator (ICD) is widely
accepted for primary and secondary prevention of severe life-
threatening ventricular tachyarrhythmia. The Heart Rhythm
Society updated appropriate use criteria for ICD therapy [1],
however the incidence, risk factors, and management of
safety margin testen <10 J (SMT) during implantable car-
dioverter defibrillator (ICD) testing are not well known.
The first small study in 1995 [2] and more previous studies
[3,4] have demonstrated that additional insertion of a subcu-
taneous array (SQA) reduces mean defibrillation thresholds
(DFT) of 20%e60%, depending on the electrode model used.
The purpose of this study was to assess the efficacy/safety
of routinely adding a subcutaneous array (Medtronic 6996SQ)
for patients with SMT <10 J during implantable cardioverter
defibrillator (ICD) testing.Methods
All consecutive patients undergoing initial ICD placement or
generator replacement from January 2007 to December 2009
were analyzed in this retrospective, single-centre analysis.
Postimplantation ICD test protocol
Devices of all 4 important international companies (Biotronic,
Medtronic, St. Jude Medical, Boston) were implanted. They
were implanted in the catheter laboratory by 5 experienced
invasive cardiologists. In all patients adequate ventricular
sensing (9mV) andpacing threshold (1V)was confirmed. In
the absence of absolute contraindications (eg thrombus for-
mation in the left atrial appendage (LAA) or the left ventricle
(LV)), an intra-operative ICD testing was routinely performed
to prove a correct sensing, processing, shock delivery and
termination of an induced VF. Our protocol for intra-operative
ICD testing required at least one induction of VF with suc-
cessful first shock terminating VF at a safetymargin of at least
10 Joule (J) below the maximum output of the implanted de-
vice. If the first shockwas not successful, a second shock at the
maximum output of the device was delivered. In case this
shock was still not successful an external defibrillation with
360 J biphasic shock was added. Patients with the need of a
second shock at the maximum output or an external defibril-
lation to terminate induced VF were considered as ineffective
SMT and were included in our study. Further management of
these patients included intra-operative right ventricular lead
reposition or an ICD-system modification such as addition or
subtraction of the superior vena cava (SVC) shock coil and
polarity reversal, respectively. In case the SMT was still inef-
fective, the implantation of a subcutaneous electrode array,
considered to be the most effective method for reducing defi-
brillation threshold, was planned.
Subcutaneous electrode array Medtronic 6996SQ
The subcutaneous array electrode Medtronic 6996SQ consists
of a single defibrillating coil of 25 cm length and has adiameter of 7.5 F, and an electrical cord ending with a 3.2 mm
connector type DF-1. Total length of the electrode is 41 cm or
58 cm. That system is connected to the SVC socket of the
implanted ICD. If a dual-coil intravascular lead is used, the
subcutaneous electrode may be connected through the Y-
connector to the SVC socket together with the proximal coil of
the intravascular lead.
Implantation procedure of the 6996SQ electrode
The patient was lying flat, with the left upper limb abducted
and an additional support under the left scapula. Local anes-
thesia was applied in the ICD pocket and along the designed
course of the subcutaneous electrode. An incision was made
in 10 cmdistance of the ICD pocket. A stainless steel tunneling
tool (6996ST provided by the manufacturer together with the
electrode) with a dedicated sheath on was shaped appropri-
ately and introduced via the small incision and further into
the subcutaneous tissue along the chest wall, and towards the
region below the inferior angle of the left scapula. Then the
tunneling tool was removed and the electrode with an intro-
ducer inside was inserted into the sheath. Following that, the
sheath was removed with a dedicated slittering tool, and the
electrode itself was sutured in the pocket in a manner typical
for intravascular leads. The electrode was tunneled from the
incision into the ICD pocket and connected to the SVC socket
of the ICD. Ideally the electrode along its course remained in
the projection of the chest, and its end is located as close to
the vertebral column as possible. In case of right sided ICD
implantation the procedure itself does not differ from left
sided implantations; however, the final tunneling to the ICD
pocket has to be performed across the thorax and the end of
the SQ array is located much more lateral because of the
limited length of the array (Fig. 1).
Statistical analysis
The study group consisted of all patients with SMT <10 J,
whereas the control group included all patients who did not
develop this problem. Continuous variables were reported as
mean value ± standard deviation or median and interquartile
ranges (25the75th percentiles) where appropriate. Categorical
variables were presented as absolute (n) and relative (%) fre-
quencies. Normal distribution of variables was assessed using
the D'Agostino-Pearson omnibus normality test. Comparisons
of continuous variables were made with the appropriate two-
sample test; Student-t-test in cases where the variable was
normally distributed. Otherwise, the KruskaleWallis test was
used to identify risk factors for ILM. A probability value of
p  0.05 was considered statistically significant. Statistical
analysis was performed using the GraphPad Prism version
6.02 for windows (GraphPad Software, La Jolla, California,
USA).Results
A total of 1221 patients underwent heart rhythm device im-
plantation during the study period. Out of 632 analyzed ICD-
recipients, 16 (2.5%) had no intra-operative defibrillation
Fig. 1 e Chest x-ray image (posterior-anterior and lateral projection) of an ICD device plus subcutaneous array electrode
(Panel A and B: left sided ICD implantation; Panel C and D: right sided ICD implantation).
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thrombus and 7 (1.1%) due to decision of the operator (mainly
atrial fibrillation with ineffective oral anticoagulation)].
Included in this retrospective analysis were 616 consecutive
patients who received SMT following transvenous ICD im-
plantation or ICD replacement. The population is described in
Table 1; the device flow chart is shown in Fig. 2.
Effective defibrillation SMT was performed with a mean
energy of 20.8± 2.3 J. In 16 patients (2.6%) inducedVF could only
be terminated with the maximum energy of the implanted
device or with an external defibrillation (Table 1). There
occurred no severe complications (death, major or minor
strokes or cardiogenic shock) in any of the 616 SMT performed.
The patients with ineffective SMT were younger (66.7 ± 10.6
years versus 54.6 ± 16.5 years; p ¼ 0.003) and in univariate
analysis they were less likely to have CAD as underlying diag-
nosis (31.3% versus 56.8%; p ¼ 0.05). There was a trend for
higher incidence of ineffective SMT in patients with myocar-
ditis/inflammatory dilated cardiomyopathy compared to other
form of non-ischemic cardiomyopathy (62.5% versus 37%),
however this was not statistically significant (p ¼ 0.06). Vari-
ableswithout impacton theefficiencyofSMT includedwhether
or not patients had a LVEF 20%, had a secondary preventive
indication for ICD, were incomplete revascularized, had more
than one main vessel significantly diseased and were taking a
medication with amiodarone, respectively (Table 1).
In all 16 cases, other methods to improve SMT prior to SQ
array insertion were attempted but failed for all patients:reversing shock polarity [n ¼ 15 (93.8%)], removing the supe-
rior vena cava coil [n ¼ 14 (87.5%)], reprogramming shock
waveform [n ¼ 9 (56.3%)], and repositioning right ventricular
lead [n ¼ 9 (56.3%)]. Addition of the SQ array successfully
increased SMT to within safety margin for all patients
(30.9 ± 2 J without versus 21 ± 3 J with SQ array; p < 0.001). No
complications related to subcutaneous array implantation
occurred in our series.
Arrhythmic events during follow-up
The mean follow up was 48.1 ± 21 months and no death or
resuscitation occurred during the follow up period. There
were no problems (e.g. lead fracture, infection) noticed related
to the subcutaneous array. Antiarrhythmic medication was
equally balanced between both groups (Table 2). In general,
there were more events in patients with effective SMT (23.2%
versus 12.5%; p ¼ 0.55). There were significantly more
adequate therapies in patients with effective SMT (21.4%
versus 0%; p¼ 0.05), whereas inadequate therapies weremore
frequently encountered in patients with initial ineffective
SMT (12.5% versus 0.8%; p ¼ 0.01).Discussion
Our study represents a large data-set evaluating the impact of
adding a subcutaneous array in patients with ineffective






Number, n (%) 616 600 (97.4) 16 (2.6)
Sex
Male, n (%) 469 456 (76) 13 (81.3) 0.77
Female, n (%) 147 144 (24) 3 (18.7)
Age (years) Mean (±SD) 66.4 (±11) 66.7 (±10.6) 54.6 (±16.5) 0.0003
Median (IQR) 69 (60e74) 69 (62e74) 54 (41e69)
LVEF (%) Mean (±SD) 31 (±12.4) 31 (±12.5) 26.9 (±9.0) 0.86
Median (IQR) 30 (22e35) 30 (23e35) 30 (20e35)
LVEF 30%, n (%) 370 (59.9) 359 (59.8) 11 (68.8) 0.61 (>30% vs 30%)
LVEF 20%, n (%) 284 (46) 279 (46.5) 5 (31.2) 0.31 (>20% vs 20%)
BMI (kg/m2) Mean (±SD) 28.4 (±4.7) 28 (±4.7) 29 (±4.0) 0.68
Median (IQR) 28 (17e28) 28 (25e31) 29 (25.5e33)
Indication Primary prevention n (%) 466 (75.7) 453 (75.5) 13 (81.3) 0.77
Secondary prevention n (%) 150 (24.3) 147 (24.5) 3 (18.7)
Type of arrhythmia for secondary
prevention n (%)
sustained VT 108 (72) 107 (72.8) 1 (33.3) p ¼ 0.19 (VT vs VF)
VF 42 (28) 40 (27.2) 2 (66.7)
SMT-energy (J) Mean (±SD) 21 (±2.3) 20.8 (±2.3) 30.9 (±2.0) 0.0001
Median (IQR) 20 (20e22) 20 (20e20) 30 (30e30)
Diagnosis
Non CAD, n (%) 270 (43.5) 259 (43.2) 11 (68.8)
DCM (myocarditis), n (%) 232 (37.7) 222 (37) 10 (62.5) 0.06 (myocarditis vs
nonmyocarditis)Other CM (non myocarditis), n (%) 38 (6.2) 27 (6.2) 1 (6.3)
CAD, n (%) 346 (56.2) 341 (56.8) 5 (31.3) 0.05 (nonCAD vs CAD)
Complete revascularized, n (%) 196 (56.3) 192 (56.3) 4 (80)
Not complete revascularized, n (%) 150 (43.7) 149 (43.7) 1 (20) 0.18 (complete vs
in- complete
revascularized)
Medication Amiodarone medication, n (%) 123 (20) 118 (19.7) 5 (31.3) 0.34
No amiodarone, n (%) 493 (80) 482 (80.3) 11 (68.7)
BMI: body mass index; CAD: coronary artery disease; CM: cardiomyopathy; DCM: dilated cardiomyopathy; IQR: interquartile range; LVEF: left
ventricular ejection fraction; n: number; n.s.: not significant; pp: primary prevention; SMT: safety margin test; SD: standard deviation; sp:
secondary prevention; VF: ventricular fibrillation; VT: ventricular tachycardia.
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ular, the relevant findings of this study are (1) SQ array im-
plantation decreases DFT bymean 10 J to within safetymargin
for all patients; (2) the incidence of ineffective SMT was
negatively affected by younger age and non-ischemic cardio-
myopathy; and (3) there were no severe array related adverse
events in any of the patients undergoing SQ array placement.Efficacy of subcutaneous array implantation
Unsuccessful intra-operative SMT testing in terms of at least
less than 10 J safety margin or necessity for external defibril-
lation was observed in 2.8% of our patients. This is signifi-
cantly lower compared to the numbers in older publications
[5,6] reporting consistently proportions of ~6% of the pa-
tients undergoing ICD implantation. Such patients in our
study were younger and had underlying non-ischemic car-
diomyopathy, although widely accepted “risk factors” pre-
dicting a SMT <10 J are not available. A study of Trusty et al.
failed to reveal any correlation of preoperative characteristics
with SMT <10 J [7]. However, several authors reported a wide
spectrum of potential risk factors for SMT <10 J including high
body-mass-index, large left ventricular diameter, or amio-
darone medication [8,9]. It is important to remember that
several drugs used for general anesthesia during theimplantation procedure can increase the minimally effective
defibrillation threshold [10]. Off note, habitual cocaine use can
cause high defibrillation thresholds [11], but this might not be
relevant in daily clinical practice.
Consistent with other studies [2,3,6], adding a subcutane-
ous array in our study increased SMT by a mean of 10 J (from
31 J to 21 J). The higher the number of “fingers” of the subcu-
taneous array the lower the effects of the SMT was the main
conclusion of a randomized study investigating the efficacy of
different array types [3]. The subcutaneous array electrode
Medtronic 6996SQ used in our series providing a single defi-
brillation coil might be potentially the most effective tool to
solve the problem of high DFT.To test or not to test
In 3 decades of clinical use of the implantable cardioverter
defibrillator, defibrillation threshold testing has remained an
integral part of the initial implantation procedure [12]. The
prevailing rationale for the routine evaluation of SMT has
been to ensure appropriate sensing of ventricular fibrillation,
system integrity, and effective defibrillation [12]. Early in the
development of the transvenous ICD, defibrillation threshold
testing was performed by connecting the transvenous lead to
an external cardioverter defibrillator using high-voltage
Fig. 2 e Device flow chart (CCM: cardiac contractility
modulation; HRD: heart rhythm devices; ICD: implantable
cardioverter defibrillator; ILR: implantable loop recorder;
SMT: safety margin testing; SQ: subcutaneous).
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testing was successful [13]. Over time, device-based testing
could be performed. Technically, the DFT is a probabilistic
phenomenon requiring multiple shocks to determine with
precision. Clinically, the SMT is commonly approximatedwith
1 or more shocks to terminate induced ventricular fibrillation
and ensure a safety margin between the DFT and the
maximumoutput of the ICD. Inadequate safetymargins of 10 J
between the DFT and maximum ICD energy delivery haveTable 2 e Follow up data.
All
Follow up, n (%) 550 (89.3)
FU duration (months) Mean (±SD) 48.1 (±21)




Events during FU, n (%) 126 (22.9)
Inadequate therapy 6 (1.1)
Adequate therapy 114 (20.7)
ATP 58 (10.6%)
Shock delivery 36 (6.6%)
ATP and shock delivery 20 (3.6%)
VT ablation 6 (1.1%)
FU: follow up; ATP: anti tachycardia pacing. Additional abbreviations in Tbeen associated with worse clinical outcomes [14]. Contem-
porary ICD systems using active cans, biphasic waveforms,
and intravascular high-voltage leads have considerably low-
ered the incidence of SMT <10 J [15,16]. The reliability of cur-
rent ICD systems has led implanting physicians to abandon
the practice of routine testing of defibrillation efficacy before
hospital discharge and annually [12,13]. Based on a growing
body of evidence the clinical utility of the determination of
defibrillation efficacy during de-novo implants has been
questioned in observational studies [15,17] as well as in ran-
domized trials [18,19]. Currently, there is a widely accepted
consensus that SMT at the time of ICD-implantation, although
it seems to be safe, has no impact on post implant outcomes
and first shock efficacy. However, this does not apply to pa-
tients undergoing implantation of a subcutaneous ICD, to
patients with right sided ICD-implantation, and to patients
who might have a potential problem with their ICD-system
post implant that might warrant safety margin testing [13].
For the latter groups of patients and for patients with inef-
fective adequate ICD-shock delivery during daily life subcu-
taneous array implantation represents a very effective but low
risk method for DFT lowering.Limitations
Several limitations of the studymerit further discussion. First,
this study is subject to limitations inherent in non-
randomized retrospective studies. Second, although the
number analyzed patients undergoing ICD implantation is
high, the total number of patients finally receiving a SQ array
was low. Therefore the conclusions of our study are only
preliminary.Conclusions
Our study demonstrates that SQ array implantation in in-
dividuals with SMT <10 J decreases DFT bymean 10 J to within
safety margin for all patients, the incidence of SMT <10 J was
affected by younger age and non-ischemic cardiomyopathy,
and there were no severe SQ array related adverse eventsEffective SMT (10 J) Ineffective SMT (<10 J) p-value
534 (89) 16 (100) 0.40
52.5 (±21) 43.8 (±21) 0.56
122 (22.9) 6 (37.5) 0.23
2 (0.4) 0 (0) 1.00
485 (90.8) 15 (93.8) 1.00
124 (23.2) 2 (12.5) 0.55
4 (0.8) 2 (12.5) 0.01
114 (21.4) 0 (0) 0.05
58 (10.9) 0 (0) 0.39
36 (6.7) 0 (0) 0.62
20 (3.8) 0 (0) 1.00
6 (1.1) 0 (0) 1.00
able 1.
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intra-operative safety margin testing has decreased signifi-
cantly over the past years (and will continue doing so in the
future) SQ array placement is a very effective but low risk
method for selected patients for DFT lowering.Conflict of interest
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